The Study That's Supposed to End My Argument: Ketamine-Assisted Psychotherapy vs. Ketamine Alone

A colleague recently sent me a study with a note that said, in effect: hey, look, we need to do more research. The paper found that adding psychotherapy to ketamine produced no additional benefit over ketamine alone. I've spent years arguing that the therapy is where the work happens, and that the ketamine industry scaled by cutting preparation, therapeutic presence, and integration because those are the expensive parts. So this study is, on its face, the one that's supposed to end my argument.

My colleague's response was the right one, and I agree with it: we need more research. But "more research is needed" can be a dodge, or it can be a precise statement about where the evidence actually stands. The question of ketamine-assisted psychotherapy vs. ketamine alone deserves the precise version, so let's do that here.

Moore and colleagues, publishing in the Journal of Affective Disorders, analyzed three overlapping cohorts (202, 470, and 624 help-seeking patients) who received either ketamine alone or ketamine plus psychotherapy across four to fourteen sessions. Both groups improved substantially on depression (PHQ-9) and PTSD (PCL-5) measures, with the same shape: rapid early decline, then stabilization. The trajectories didn't differ significantly between groups at 30 days, and possibly not at 180.
That's a real finding from a decent-sized real-world sample, and it deserves to be taken at face value before it's taken apart. If you practice KAP, the least comfortable reading is also a legitimate one: maybe the medicine is doing more of the work than our model says, and the therapy hours we bill alongside it are doing less.

Taking a finding seriously includes being precise about its limits, and this one has three that matter.

Nobody was randomized. This was an observational comparison of patients who ended up in one arm or the other. People who seek out therapy alongside ketamine, or are steered toward it, may differ systematically from those who don't, in severity, resources, or expectations. The design can't separate the treatment's effect from the selection.

"Psychotherapy" is undefined. The paper doesn't specify modality, dose, or quality. KAP as practiced ranges from manualized preparation-and-integration protocols to a therapist sitting in the room during infusions. A null result for an unmeasured intervention tells us little about any specific one. You can't conclude that structured integration work adds nothing from a dataset where "therapy" might mean almost anything.

The follow-up window favors the drug. Ketamine's symptom effect is rapid and front-loaded; that's its signature. If therapy earns its keep anywhere, the most plausible place is durability: relapse prevention, what clients build during the neuroplastic window that outlasts the drug effect. A 30-day PHQ-9 trajectory is nearly the worst place to look for that. The authors themselves note an exploratory wrinkle pointing the same direction: outcomes appeared to differ by demographic subgroup, with younger women doing better with combined treatment. Exploratory means exploratory, but it's a reminder that "no average difference" and "no difference" aren't the same claim.

Here's what reframed the study for me. A systematic review published in Clinical Psychology Review in February 2026 examined 72 studies of ketamine-assisted psychotherapy published through 2025. Eleven were randomized controlled trials. Exactly two randomized the psychotherapy component itself. Neither found clear added benefit. Twenty-four of the 72 studies fit no established therapeutic paradigm at all.

Notice who benefits from each answer. If therapy adds nothing, the telehealth ketamine industry's business model (medicine by mail, no therapist in the loop) is vindicated, and its biggest cost center stays cut. If therapy is essential, the training industry's $2,000-to-$15,000 KAP certificates become mandatory equipment, and every infusion clinic needs to hire. Both sides produce confident content about this question. Neither is a neutral party.

Neither am I. I teach courses on this work, including integration, so I have a stake in therapy mattering. The difference I can offer isn't neutrality. It's disclosure, and a commitment to update when the evidence says to. If NCT06559826 comes back null with a well-defined therapy arm, I'll write about that too. That's not an accusation of anyone; it's a structural observation about a field where the evidence is thin enough that incentives fill the gaps.

For clinicians doing or considering this work, my read of where the evidence actually leaves us:

• Stop claiming synergy as established fact. "Preliminary research suggests" and "in my clinical experience" are honest framings; "studies show KAP outperforms ketamine alone" currently is not.
• Keep the structure. Preparation, monitoring during dosing, and integration appear in every protocol with good outcomes and carry the safety load regardless of the synergy question. Screening and risk assessment aren't waiting on an RCT.
• Be honest with clients about what's known. Informed consent is ongoing, and "the medicine has strong short-term evidence; the added value of the therapy component is still being tested" is a consentable sentence. Clients tolerate uncertainty better than they tolerate discovering it later.
• Watch durability, not just response. In your own practice data, the interesting comparison isn't week two. It's month six, and who relapsed.

The study my colleague sent doesn't end my argument. It does something more useful: it demands the argument be made with evidence instead of conviction. We need more research, said precisely, not defensively.

The controlled evidence cannot yet confirm it. Of 72 ketamine-assisted psychotherapy studies reviewed through 2025, only two randomized the psychotherapy component, and both were null. Protocols with the best outcomes consistently include preparation, monitoring, and integration, but whether those are active ingredients or simply good clinical practice has not been isolated.

Moore and colleagues compared ketamine alone with ketamine plus psychotherapy across three real-world cohorts. Both groups improved substantially on depression and PTSD measures, with no significant difference at 30 days. But nobody was randomized, "psychotherapy" was undefined, and the short follow-up window favors ketamine's rapid, front-loaded effect over where therapy would most plausibly help: durability.

That synergy claim is not established by controlled evidence. It rests on two small randomized trials, both null, plus many uncontrolled studies and clinical conviction. Honest framing is "preliminary research suggests" or "in my clinical experience," not "studies show KAP outperforms ketamine alone." A registered trial (NCT06559826) is finally testing the question directly.

Yes. Preparation, monitoring during dosing, and integration appear in every protocol with good outcomes and carry the safety load regardless of the synergy question. Screening and risk assessment are not waiting on a trial. Tell clients honestly that the medicine has strong short-term evidence while the added value of the therapy component is still being tested.

Peter H. Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances.

If you practice KAP or are considering it: the Ethical Guidelines For Ketamine Clinicians course (2 CEs) covers consent, scope, and risk in exactly this kind of uncertainty. For ongoing evidence updates without the hype, the PAE newsletter is where I track studies like these as they publish; the signup is just below.